The first Parkinson’s patient has been dosed in a Phase 1 clinical trial that is testing IkT-148009, an investigational oral therapy being developed by Inhibikase Therapeutics to slow or stop disease progression.
“We are pleased to begin dosing patients in our Phase 1b study,” Milton Werner, PhD, Inhibikase‘s president and CEO, said in a press release.
Looks promising. Thank you for sharing.
It's moving to a Phase 2 randomized, double-blind, 12-week dosing trial assessing safety & tolerability in untreated
Stem Cells TrialsResults of a Phase 1b trial of MODAG's oligomer modulator anle138b evaluating the safety tolerability in healthy volunteers
A (minor) update by Inhibikase Therapeutics on their Phase 2 trial of Risvodetinib (IkT-148009) for Parkinson's Disease.
Anyone participating in the Buntanetap Phase 3 trial?Phase 1 trial of VRG50635 - a novel therapeutic discovered & "delivered into the clinic in just 4 years" by an AI-powered platform
